ライフサイエンスコーパス: abstinent

1 ent individuals seeking to become and remain abstinent.

2 patients with alcoholic cirrhosis who remain abstinent.

3 hemical validation were considered to not be abstinent.

4 inning prizes increased with continuous time abstinent.

5 ubsequently relapsed from those who remained abstinent.

6 ance of connecting with individuals who were abstinent.

7 nd experience greater difficulties remaining abstinent.

8 es when they were nicotine sated or nicotine abstinent.

9 hose cravings conflict with a goal to remain abstinent.

10 correlate with severity of use or months MA abstinent.

11 le smoking as usual and 3 days while smoking abstinent.

12 ith ARC, whereas IL-4 production prevails in abstinents.

13 e, whereas only one sequence was targeted in abstinents.

14 day (-1.62) and a higher percentage of days abstinent (11.27%) than those who received placebo.

15 e college alcohol abusers had died, 11% were abstinent, 11% were controlled drinkers, and 59% were kn

16 core city alcohol abusers had died, 30% were abstinent, 11% were controlled drinkers, and only 28% we

17 inued their therapy; of the 157 who were not abstinent, 122 were rerandomized and 35 who did not retu

18 inued their therapy; of the 191 who were not abstinent, 151 were rerandomized, and the 40 who did not

19 day (-2.63) and a higher percentage of days abstinent (16.99%) than all other genotype and treatment

20 cohol abstinence pre-LT of 54 days, 74% were abstinent, 16% had slips only, and 10% had sustained alc

21 ; effect size=0.780), and percentage of days abstinent (18.18%; effect size=0.683).

22 l's RT on a Stroop task in 30 currently drug-abstinent (3 months to 2 years) MA abusers compared with

23 inks per drinking day and percentage of days abstinent, 5'-HTTLPR and rs1042173 variants interacted s

24 management (n = 157) had lower percent days abstinent (66.6) than those receiving placebo plus medic

25 es (aged 38 +/- 11 years; 6 female, 14 male; abstinent 7 +/- 1 days) and 27 people who never smoked c

26 to placebo in increasing percentage of days abstinent (70.10 vs 50.20; P =.02) and total days abstin

27 management (n = 309) had higher percent days abstinent (80.6, 79.2, and 77.1, respectively) than the

28 day (-1.45) and a higher percentage of days abstinent (9.65%) than all other genotype and treatment

29 ed patients with primary alcohol dependence, abstinent a median of 8 days before randomization.

30 icit memories of that experience even in the abstinent addict.

31 caine craving is a major cause of relapse in abstinent addicts.

32 diction is limited by a high relapse rate in abstinent addicts.

33 nditioning is a major trigger for relapse in abstinent addicts.

34 Similar to PBMCs in abstinents, ADH peptides induced weak T-cell proliferati

35 antigen DR, CD80, and CD86 were increased in abstinent AH patients.

36 ne abnormalities were reversed by day 360 in abstinent AH patients; however, plasma levels of tumor n

37 olled, crossover design approach was used in abstinent alcohol dependent, abstinent poly-drug depende

38 Abstinent alcohol- (n = 30) and methamphetamine-dependen

39 In this study, 131 recently abstinent alcohol-dependent outpatients were treated wit

40 hibition and underlying neural correlates in abstinent alcohol-dependent patients (AD) (n = 16) and h

41 D3 availability was compared between 16 male abstinent alcohol-dependent patients and 13 healthy non-

42 Forty-five abstinent alcohol-dependent patients in treatment and 50

43 In a double-blind randomized design, 32 abstinent alcohol-dependent patients received either bia

44 During loss anticipation, abstinent alcohol-dependent subjects showed lower activi

45 Eighty-one abstinent, alcohol-dependent patients completed a functi

46 c resonance imaging (fMRI) from 42 long-term abstinent alcoholic (25 women) and 46 nonalcoholic (24 w

47 Male (n = 18) and female (n = 10) abstinent alcoholic cirrhotic patients were studied and

48 We studied 131 recently abstinent alcoholics.

49 d similar immune responses to those who were abstinent, among both subjects with HIV/HCV and subjects

50 performed in 24 chronic marijuana users (12 abstinent and 12 active) and 19 age-, sex- and education

51 -up period of 48 weeks, 37 patients remained abstinent and 53 patients relapsed as indicated by the A

52 Non-abstinent and abstinent smokers (those abstaining for ap

53 8 participants in the varenicline group were abstinent and continued their therapy; of the 157 who we

54 hase, 54 participants in the CNRT group were abstinent and continued their therapy; of the 191 who we

55 ported drinking measures (percentage of days abstinent and drinks per drinking day) along with the la

56 ir interaction as moderators of frequency of abstinent and heavy drinking days during treatment, asse

57 lescents who have never used drugs to remain abstinent and interventions to help adolescents who are

58 t two laboratory sessions, one while smoking abstinent and one while smoking ad libitum, to assess th

59 splant drinking reported themselves as again abstinent and recommitted to sobriety when interviewed.

60 with results comparable to patients who are abstinent and those with no drug-use histories, especial

61 e of heavy drinking days, percentage of days abstinent) and plasma gamma-glutamyl transferase, an obj

62 response (ie, retained in treatment, opioid abstinent, and receiving naltrexone at the end of the st

63 oduction was lower in active drinkers versus abstinents, and IL-17 production was higher.

64 DRN-MOR neurons of abstinent animals showed a downregulation of genes invol

65 Although both extinguished and abstinent animals showed a reduction in long-term potent

66 aracterize their adapted phenotype in opioid abstinent animals, and hopefully position these primary

67 lenge modified FC faster and more broadly in abstinent animals, demonstrating brainwide adaptations o

68 e 26-week follow-up (22 [13.8%] vs 14 [8.7%] abstinent; AOR, 1.79 [95% CI, 0.85-3.80]).

69 months, and 115 (57 women) of them remained abstinent at 12 months.

70 ssation were significantly less likely to be abstinent at 4 weeks than those who preferred abrupt ces

71 re significantly more likely to be confirmed abstinent at 6-month follow-up: 21.3% versus 6.8% in the

72 nd 220,000 (95% CI 159,000-282,000) remained abstinent at follow-up.

73 more likely than those in group 1 to remain abstinent at follow-up.

74 other quit attempt among those (n = 331) not abstinent at six months was not significantly different

75 Somewhat fewer patients were abstinent at the 6-month follow-up; however, the differe

76 t week 2 had 4.6 times greater odds of being abstinent at week 12 (37 of 129 [28.7%] abstinence) than

77 h follow-up assessment, 27 patients remained abstinent, but 33 had relapsed.

78 sessed D(2/3) availability and DA release in abstinent cannabis users compared with control subjects

79 Thirteen abstinent CD and 13 healthy participants underwent MRI s

80 in cortical regions of interest in recently abstinent CDSs (n = 24) and healthy control subjects (n

81 or) markers of 5-HT transmission in recently abstinent chronic MDMA users compared with matched healt

82 We conducted a systematic evaluation in 72 h abstinent, chronic cannabis users (N=74) and nonusing co

83 These data suggest that in abstinent cigarette smokers, nicotine augments initial r

84 ubjective fatigue in n = 18 healthy, briefly abstinent, cigarette smokers scanned repeatedly in a pla

85 At 12 months, the annual cost per abstinent client was $16,485, $9,804, and $11,818 for th

86 roglial activation in a group of 15 recently abstinent cocaine abusers and 17 matched healthy control

87 f this observation to relapse and outcome in abstinent cocaine abusers.

88 orcement and that D2 receptor dysfunction in abstinent cocaine addicts may, in part, be determined by

89 tors (PAM) may reduce cue-induced relapse in abstinent cocaine addicts.

90 for reducing cue-induced cocaine craving in abstinent cocaine addicts.

91 tecture, and decreases daytime sleepiness in abstinent cocaine users.

92 in 58 CTL, 28 current cocaine users/CUD+, 32 abstinent cocaine users/CUD-, and 30 individuals with HU

93 elevation in striatal V3" values in acutely abstinent cocaine-abusing subjects relative to compariso

94 s were altered in acutely (96 hours or less) abstinent cocaine-abusing subjects, as suggested by post

95 nd neutral-relaxing-imagery conditions in 30 abstinent cocaine-dependent individuals (16 women, 14 me

96 saline infusion in three cohorts of 2-4 week abstinent cocaine-dependent participants (n = 93) and he

97 ic acid (HVA) were determined in 30 recently abstinent cocaine-dependent patients and 69 healthy comp

98 Recently abstinent cocaine-dependent patients may show dysregulat

99 f dopaminergic neurotransmission in recently abstinent cocaine-dependent patients.

100 VMAT2 availability in a group of 12 recently abstinent cocaine-dependent subjects and matched healthy

101 Fifteen healthy comparison subjects and 13 abstinent cocaine-dependent subjects underwent resting s

102 s in the varenicline group were continuously abstinent compared with 10.3% in the placebo group (OR,

103 s in the varenicline group were continuously abstinent compared with 13.2% in the placebo group (OR,

104 icipants in the gradual-cessation group were abstinent compared with 22.0% (CI, 18.0% to 26.6%) in th

105 icipants in the gradual-cessation group were abstinent compared with 49.0% (CI, 43.8% to 54.2%) in th

106 The RAI was significantly lower in the abstinent compared with the smoking satiety states (left

107 eceiving FBT (16 [39%]) were binge-and-purge abstinent compared with those receiving SPT (7 [18%]) (P

108 ate fMRI scans during both satiated and 24-h abstinent conditions, prior to engaging in a 3-week quit

109 otinized cigarette smoking conditions to the abstinent conditions.

110 1.54; F1,67 = 19.33; P < .001) and 28.8 more abstinent days (Cohen d = 0.72; 95% CI, 0.25-1.17; F1,67

111 negative urine samples (p<0.0001) and opioid-abstinent days (p<0.0001) favoured BUP-NX compared with

112 measured with proton MRS at baseline and on abstinent days 7 and 21 in conjunction with measures of

113 JNJ-39393406 did not increase the number of abstinent days nor reduce total smoking exposure.

114 ly reduced heavy drinking days and increased abstinent days relative to placebo.

115 0.028, d = 0.49 95%CI (0.04-0.93), 12.9 more abstinent days)] and was driven by the 90 mg/day dose.

116 f counseling to reduce drinking and increase abstinent days.

117 f counseling to reduce drinking and increase abstinent days.

118 7 = 5.65; P = .02) and abstinence (10.0 more abstinent days; Cohen d = 0.57; 95% CI, 0.11-1.02; F1,67

119 ostsynaptic currents (sEPSC) was elevated in abstinent drinkers compared with controls, indicating in

120 CeA neurons from abstinent drinkers displayed an elevated baseline sponta

121 rvocellular PVN neurons in both controls and abstinent drinkers, suggesting a lack of tolerance to ac

122 frequency of sIPSCs in controls, but not in abstinent drinkers, suggesting a tolerance to ethanol-en

123 In abstinent drug addicts, cues formerly associated with dr

124 ed patients will respond to treatment, which abstinent drug users will relapse, or which patients wil

125 In abstinent drug users, relapse is often precipitated by r

126 Persons with alcoholism who are abstinent exhibit persistent impairments in the capacity

127 ngulate cortex, regardless of the time spent abstinent (F(2,34) = 12.61; P<.001).

128 with an acute coronary syndrome (ACS) remain abstinent following discharge.

129 okers and 6 heavy smokers (>14 cigarettes/d; abstinent for >36 h).

130 king or abstinent for <6 months, and 13 were abstinent for >6 months) and hepatic mononuclear cells (

131 cirrhosis (ARC; 12 were actively drinking or abstinent for <6 months, and 13 were abstinent for >6 mo

132 6%) were abstinent for 1 week, 15 (20%) were abstinent for 1 month, 12 (16%) were abstinent for 6 mon

133 5%) were abstinent for 2 days, 20 (26%) were abstinent for 1 week, 15 (20%) were abstinent for 1 mont

134 re abstinent for 6 months, and 10 (13%) were abstinent for 1 year.

135 dividuals addicted to cocaine, 19 (25%) were abstinent for 2 days, 20 (26%) were abstinent for 1 week

136 s in the high-dose condition remained opioid-abstinent for 4 consecutive weeks, as compared with 8 (1

137 %) were abstinent for 1 month, 12 (16%) were abstinent for 6 months, and 10 (13%) were abstinent for

138 ine-dependent volunteers (16 women) who were abstinent for 7 to 10 days and 37 drug-free control volu

139 Former smokers in the control arm abstinent for 7 years had a 20% mortality reduction comp

140 icantly more negative samples, and they were abstinent for a longer period of time (5 versus 3 weeks)

141 The 105 outpatient volunteers were abstinent for a mean of 2 weeks prior to random assignme

142 3131 (29%) quit smoking and remained abstinent for at least 1 year.

143 red brain TSPO levels in 20 tobacco smokers (abstinent for at least 2 h) and 20 nonsmokers using a fu

144 s with multiple abstinence episodes remained abstinent for longer durations in successive episodes.

145 tors, especially because the ex-smokers were abstinent for only 25 wk on average.

146 In contrast, abstinent former METH abusers (METH(+)Tox-) receiving HA

147 At study entry, patients must have been abstinent from alcohol for 1 to 6 weeks and enrolled in

148 were a significantly greater number of days abstinent from alcohol in the ketamine group compared wi

149 stimated 20.9% (95% CI, 15.0% to 26.8%) were abstinent from cigarette smoking at follow-up, compared

150 Smokers were abstinent from cigarette smoking for 12 hours for all se

151 Abstinence indicators (negative urines, days abstinent from cocaine during follow-up) were collected

152 consecutive weeks during which patients were abstinent from illicit opioids.

153 Thus, all subjects were abstinent from marijuana and other drugs for a minimum o

154 Case participants were abstinent from MDMA use for at least 90 days as verified

155 Furthermore, fewer e-cigarette users were abstinent from nicotine products in the long term (nicot

156 results were obtained with incremental time abstinent from opioids as an outcome and with use of the

157 n opioid maintenance treatments and who were abstinent from opioids at the time of randomization.

158 Of 578 subjects, 31% were abstinent from smoking at the end of nicotine patch ther

159 s in the varenicline group were continuously abstinent from smoking compared with 17.6% in the placeb

160 atment, 461 of 784 participants (58.8%) were abstinent from smoking.

161 had end-stage liver disease and had remained abstinent from the time they were medically advised to s

162 The smokers were abstinent from tobacco for 1 1 to 17 hours.

163 Although the heterogeneity of the abstinent group biases the GWAS findings, unique varianc

164 consumption and disorder remained after the abstinent group was excluded.

165 patients were randomized to the screen time abstinent group.

166 nd white matter of 64 young asymptomatic and abstinent (> 5 months) cocaine users (34 male and 30 fem

167 tive therapeutic agents in the management of abstinent heroin addicts.

168 was lower (-1.53) and the percentage of days abstinent higher (9.73%) in LL compared with LS/SS indiv

169 widely used model of cue-elicited craving in abstinent human addicts.

170 cocaine, can produce craving and relapse in abstinent human substance abusers.

171 longitudinal drug use outcomes in initially abstinent iCUDs, as potentially generalizable to other s

172 16% (n = 4), and 20% (n = 5) of participants abstinent in the 4-, 2-, and 1-week conditions, respecti

173 29% (n = 7), and 29% (n = 7) of participants abstinent in the 4-, 2-, and 1-week conditions, respecti

174 with SAMCs (n = 341) were more likely to be abstinent in the integrated care group than the independ

175 5% CI 1.09-2.07]; p=0.01) and the proportion abstinent in the past 14 days (68 [42%] vs 31 [18%]; adj

176 We noted an effect on the percentage of days abstinent in the past 14 days (adjusted mean difference

177 centage point increase in percentage of days abstinent, incremental cost per patient of avoiding heav

178 e to relapse and continued drug use, in drug-abstinent individuals with heroin use disorder.

179 drug cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder.

180 d anxiety induced by drug-associated cues in abstinent individuals with heroin use disorder.

181 ctive cues, which can precipitate relapse in abstinent individuals.

182 ponses, urine cotinine level, number of days abstinent, lapse, and relapse were not observed between

183 tained every 6 months and use categorized as abstinent, light (1-3 drinks/week), moderate (4-7 drinks

184 cipation stage, individuals with AUD who are abstinent long-term present persistent sleep disturbance

185 Compared to HCs, abstinent MADs showed increased fALFF and ReHo values in

186 ver, 100% of alcoholic patients who remained abstinent maintained long-term response, compared with 3

187 We recruited 13 abstinent male AD and 15 control participants who underw

188 e frontal and medial cerebellar regions than abstinent marijuana users and greater usage of the reser

189 eater activation in the active compared with abstinent marijuana users demonstrates a neuroadaptive s

190 e compared with control subjects, active and abstinent marijuana users showed decreased activation in

191 The 45 abstinent MD showed patterns of insula activation during

192 Nineteen abstinent MDMA users and 21 control subjects participate

193 ferences in 5-HT transporter binding between abstinent MDMA users and participants in the control gro

194 5-HT neurotoxicity are not fully understood, abstinent MDMA users have been found to have subtle cogn

195 1.21, 3.00]; p = 0.006) and percent of days abstinent (mean percent [SD] 71.0% [38.2] versus 55.0% [

196 id withdrawal and helping patients to remain abstinent Methadone maintenance and newer approaches usi

197 The present study reports on 12 abstinent methamphetamine abusers and 12 age-, gender-,

198 Compared with controls, abstinent methamphetamine and methcathinone users had si

199 stinence (1 year to 5 years) and 16 recently abstinent methamphetamine users (1 month to 6 months) we

200 Fifteen recently abstinent methamphetamine users and 15 healthy controls

201 s were performed in 10 control subjects, six abstinent methamphetamine users, four abstinent methcath

202 imaging can be used to predict relapse among abstinent methamphetamine-dependent (MD) individuals.

203 s, six abstinent methamphetamine users, four abstinent methcathinone users, and three patients with P

204 Nicotine-abstinent mice displayed reduced locomotor activity.

205 l effects of VU0155041 treatment in morphine abstinent mice were correlated with restored expression

206 r effects of facilitating mGluR4 activity in abstinent mice.

207 blunted locomotor sensitization in morphine abstinent mice.

208 erence but increased stereotypies in cocaine abstinent mice.

209 effects of NPS are enhanced in acute ethanol abstinent mice.

210 utamen and NAc of morphine, but not cocaine, abstinent mice.

211 Twelve abstinent opiate-dependent subjects listened to audiotap

212 CDS scores of those individuals who remained abstinent or drank during the trial.

213 sumed heavy use (RHU) and 29 others remained abstinent or drank minimally (treatment sustainers [TS])

214 On percentage of days abstinent or negative consequences of substance use, TEL

215 f 47) in the placebo group were continuously abstinent (OR, 3.4; 95% CI, 1.02-13.6; P = .03).

216 f 47) in the placebo group were continuously abstinent (OR, 4.6; 95% CI, 1.5-15.7; P = .004), and fro

217 Regulatory agencies are considering non-abstinent outcomes as efficacy indicators in clinical tr

218 the MOUD+A-CHESS arm were more likely to be abstinent over time (b=0.28, SE=0.09) than those in the

219 (no CBI) had an increased percentage of days abstinent (P = .07) and a decreased percentage of heavy

220 vy drinking days (p=0.0003), 26.2% more days abstinent (p=0.0003), and a log plasma gamma-glutamyl tr

221 apse (p=0.009), and maximum consecutive days abstinent (p=0.0007), with all results best for buprenor

222 ta were acquired in the same scan session in abstinent participants with CUD before residential treat

223 Compared with sexually abstinent participants, females engaging in sexual inter

224 ntal cost-effectiveness ratio per additional abstinent patient with an SAMC in the integrated care gr

225 Additional analysis with abstinent patients as a reference showed a dose effect o

226 Non-abstinent patients had significantly higher aldosterone

227 significantly higher aldosterone levels than abstinent patients.

228 nent (70.10 vs 50.20; P =.02) and total days abstinent per study week (6.74 vs 5.92; P =.03).

229 gically primary, had persisted during a past abstinent period or was long-standing, and persisted dur

230 guished: nonusers, intermittent users during abstinent periods, intermittent users during active peri

231 ortical dopamine transmission in 21 recently abstinent persons with alcohol dependence and 21 matched

232 ach was used in abstinent alcohol dependent, abstinent poly-drug dependent and healthy control volunt

233 Sixteen recently abstinent, psychiatrically healthy cannabis-using partic

234 61-8048 prevented relapse-like behavior when abstinent rats or monkeys were reexposed to nicotine and

235 In U-50,488H-abstinent rats, the binding of [3H]MK-801 was increased

236 nsity of the shell in either extinguished or abstinent rats.

237 cb core neurons from alcohol- versus sucrose-abstinent rats.

238 of brain regions of U-50,488H-tolerant and -abstinent rats.

239 ificantly reduced when drug-experienced, but abstinent, rats are given just 5 min daily prior access

240 Divergent results across abstinent, recreationally using, and addicted population

241 ine acute influences on reward processing in abstinent, recreationally using, and addicted population

242 -contingent oxycodone-associated cues during abstinent reinstatement of drug-seeking behavior.

243 al responses, cotinine level, number of days abstinent, relapse, or lapse.

244 thalamic and hypothalamic stress circuits in abstinent rhesus males.

245 olerance to ethanol-enhanced GABA release in abstinent rhesus monkeys with a history of chronic ethan

246 l parameters were compared between sated and abstinent scans.

247 waver in their commitment to remain tobacco abstinent should be targeted for tobacco prevention inte

248 icantly greater IQ decline relative to their abstinent siblings.

249 Overall, patients were abstinent significantly longer when receiving desipramin

250 Non-abstinent and abstinent smokers (those abstaining for approximately 12

251 orking memory task [2-back task (2BT)] in 11 abstinent smokers and 11 ex-smokers.

252 rug, placebo-controlled design, 24 overnight-abstinent smokers and 20 nonsmokers underwent approximat

253 A subset of fifteen recently abstinent smokers and 21 never smokers received a mid-sc

254 e were 159 (77 women) biochemically verified abstinent smokers at 6 months, and 115 (57 women) of the

255 Beta2*-nAChR availability in recently abstinent smokers correlated with the days since last ci

256 Thus findings fit a recent proposal that abstinent smokers show decreased ability to divert cogni

257 long with subtle behavioral deficits, mildly abstinent smokers showed less task-induced brain activat

258 When demand for inhibitory control was high, abstinent smokers showed no deficits.

259 By contrast, acutely abstinent smokers showed performance deficits in easier

260 ity associated with cognitive flexibility in abstinent smokers was restored to the level of nonsmoker

261 Computational modeling indicated that abstinent smokers were biased toward response shifting a

262 After nicotine infusion, abstinent smokers with the withdrawal risk allele experi

263 awal period, which may facilitate relapse in abstinent smokers, yet the molecular neuroadaptation(s)

264 anxiety is a prominent withdrawal symptom in abstinent smokers, yet the neuroanatomical and molecular

265 own-regulated by varenicline and nicotine in abstinent smokers.

266 , suggesting higher beta2*-nAChR in recently abstinent smokers.

267 cal valuation of nondrug and drug rewards in abstinent smokers.

268 g drug-stimulus pairings specifically in the abstinent state, indicating a critical role for incentiv

269 gurations were stable across sated and acute abstinent states (indicative of a "trait" circuit adapta

270 ed reinstatement of drug-seeking behavior in abstinent subjects (models of relapse).

271 ther assessed 32 young binge drinkers and 36 abstinent subjects with alcohol use disorders.

272 Nicotine abstinent subjects, but not nicotine-naive controls, exp

273 istory-positive women were less likely to be abstinent than MDD history-negative women, but depressio

274 had significantly greater percentage of days abstinent than those receiving placebo (51.2 vs 41.6, re

275 s significantly more pleasant while nicotine abstinent than while nicotine sated.

276 7 [1.38-3.42]), and maximum consecutive days abstinent than with placebo (mean days 59 [95% CI 43-76]

277 Among the subjects who were continuously abstinent through the end of treatment, the mean absolut

278 Participants who were abstinent throughout week 7 of open-label treatment were

279 unit (beta(2)*-nAChR) are higher in recently abstinent tobacco smokers compared with participants who

280 Forty early abstinent treatment-seeking cocaine-dependent males and

281 A total of 51 recently abstinent treatment-seeking patients with alcohol use di

282 fluid monoamine metabolite concentrations in abstinent, treatment-seeking alcoholics.

283 Recently abstinent users have been found to do poorly on neurocog

284 ormalized with duration of abstinence in the abstinent users.

285 001-January 2004 among 1383 recently alcohol-abstinent volunteers (median age, 44 years) from 11 US a

286 ual buprenorphine for 6 months or more, were abstinent while taking 8 mg/d or less of sublingual bupr

287 ing 41 patients interviewed, 21 had remained abstinent, while the other 20 had returned to some form

288 f pretransplant abstinence, 58% had remained abstinent, while the other 42% had resumed drinking.

289 pretransplant abstinence, only 30% remained abstinent, while the other 70% had resumed drinking.

290 0.75 [95% CI, 0.70-0.81]) and those who were abstinent with an AUD history (HR, 0.76 [95% CI, 0.68-0.

291 [HR], 0.72 [95%, CI, 0.66-0.77]) or who were abstinent with an AUD history (HR, 0.91 [95% CI, 0.84-1.

292 lems, Tenth Revision diagnoses: current AUD, abstinent with AUD history, at-risk drinking, lower-risk

293 ere abstinent without AUD, 9192 (13.3%) were abstinent with AUD, 13 415 (19.4%) had lower-risk consum

294 der (AUD): abstinent without history of AUD, abstinent with history of AUD, lower-risk consumption, m

295 Comparing abstinent with sated scans, smokers also exhibited signi

296 g, who had "slip" drinking, and who remained abstinent, with relapsers showing the highest scores.

297 , at-risk drinking, lower-risk drinking, and abstinent without AUD history.

298 A total of 32 290 individuals (46.6%) were abstinent without AUD, 9192 (13.3%) were abstinent with

299 on diagnoses for alcohol use disorder (AUD): abstinent without history of AUD, abstinent with history

300 safe in a 14-day clinical trial in sexually abstinent women.